Results 91 to 100 of about 939 (187)
, 2019 Background: Research has indicated that calcitonin gene-related peptide (CGRP) receptor antagonists can be effective in the acute treatment of migraine. Six major drugs are included within this category: telcagepant, olcegepant, BI 44370, rimegepant (BMS-
Fang Xu (138747), Wenjun Sun (446555)
core +1 more source
, 2019 Background: Research has indicated that calcitonin gene-related peptide (CGRP) receptor antagonists can be effective in the acute treatment of migraine. Six major drugs are included within this category: telcagepant, olcegepant, BI 44370, rimegepant (BMS-
Fang Xu (138747), Wenjun Sun (446555)
core +1 more source
Daten zum neuen CGRP-Antagonisten Ubrogepant bei akuter Migräne [PDF]
DNP - Der Neurologe & Psychiater, 2017 Ein neuer CGRP-Rezeptor-Antagonist ist in der klinischen Entwicklung. Als Alternative zu Triptanen ist er etwa gleich effektiv, aber mit besserem Vertraglichkeitsprofil.
openaire +1 more source
Patient Preference and Adherence, 2023 Oralee J Varnado,1 Tania Gulati,2 Anthony Wheeler,3 Margaret Hoyt1 1Value Evidence Outcomes – Research & Neuroscience, Indianapolis, IN, USA; 2Value Evidence Outcomes, Real World Evidence, Eli Lilly Services India, Private Limited, Bengaluru, Karnataka ...
Varnado OJ, Gulati T, Wheeler A, Hoyt M
doaj
Cyprus Journal of Medical SciencesBACKGROUND/AIMS: Migraine is treated with a variety of drugs with different pharmacological mechanisms of action. Among these drugs, calcitonin gene-related peptide (CGRP) antagonists represent a novel approach to the treatment of migraine.
Nesrin Çağlayan Duman
doaj +1 more source
Vascular Effects of Current and Novel Antimigraine Drugs [PDF]
, 2019 Migraine is a highly prevalent and disabling neurovascular disorder, that predominantly affects women, thought to be associated with a dysfunctional activation of the trigeminovascular system.
Rubio-Beltrán, A.E. (Eloísa)
core +1 more source
Journal of Education, Health and SportBackground. Migraine is a complex neurobiological disorder associated with the activation of the trigeminovascular system. Many new publications about new drugs appear, but not all of them assign the drug to the most appropriate group of patients ...
Wiktor Kowalczyk +9 more
doaj +1 more source
Novel synthetic treatment options for migraine
, 2020 Introduction: Migraine is one of the most common neurological disorders. Nowadays, the 5-HT1B/1D receptor agonists, namely triptans, are considered as the standard of care for migraine acute treatment. However, triptans have limitations in some patients,
Martelletti P. +3 more
core +1 more source
Migraine Drug Ubrogepant May Ease Preheadache Symptoms
JAMAMigraine is a crippling affecting animate nerve organs disorder characterized by repeating attacks of moderate to harsh migraine often followed by revulsion, photophobia, and phonophobia. Increasing evidence suggests that effective invasion, all the while the prodromal or preheadache step, grants permission to hinder the progression of headache attacks
openaire +3 more sources
New therapeutic options in migraine treatment
Journal of Education, Health and SportIntroduction and purpose Migraine is a common disease mostly affecting women. It has a huge influence on patients’ life strongly decreasing its quality by cause of repetitive headache episodes and often comes with unpleasant and burdensome symptoms ...
Aleksandra Kłos +9 more
doaj +1 more source